Table 2.
Variable | Model 1 | Model 2 | ||
---|---|---|---|---|
OR (95% CI) | P-value | OR (95%CI) | P-value | |
Patient-related risk factors | ||||
Age | 1.02 (1.01–1.03) | <0.001** | ||
Sex | ||||
Female | 1.06 (0.73–1.56) | 0.755 | ||
Male | — | — | ||
BMI | 1.00 (0.98–1.02) | 0.950 | ||
Laboratory-related risk actors | ||||
MMP-13 | 1.03 (0.99–1.08) | 0.166 | 1.07 (1.01–1.13) | 0.037* |
CRP (mg/L) | 1.02 (0.99–1.05) | 0.214 | 1.03 (0.99–1.07) | 0.207 |
ESR (mm/H) | 0.99 (0.98–1.01) | 0.518 | 0.99 (0.97–1.01) | 0.347 |
WBC | 1.02 (0.94–1.11) | 0.672 | 1.01 (0.90–1.13) | 0.884 |
Neu (%) | 0.99 (0.98–1.00) | 0.132 | 0.98 (0.97–1.00) | 0.061 |
Hb | 0.99 (0.98–1.01) | 0.271 | 1.00 (0.98–1.01) | 0.572 |
PLT | 1.00 (0.99–1.00) | 0.789 | 1.00 (0.99–1.00) | 0.041* |
Alb (g/L) | 1.00 (0.98–1.02) | 0.925 | 1.00 (0.97–1.03) | 0.895 |
ALT (U/L) | 1.00 (0.98–1.02) | 0.840 | 0.99 (0.96–1.01) | 0.308 |
AST (U/L) | 1.01 (0.97–1.04) | 0.743 | 1.03 (0.98–1.08) | 0.252 |
Cr (mmol/L) | 1.00 (1.00–1.00) | 0.515 | 1.00 (1.00–1.00) | 0.463 |
PT(S) | 0.35 (0.08–1.54) | 0.176 | 0.84 (0.14–5.09) | 0.854 |
PT-A | 0.92 (0.81–1.03) | 0.172 | 0.99 (0.85–1.15) | 0.865 |
INR | 1.00 (0.93–1.07) | 0.950 | 1.01 (0.92–1.11) | 0.801 |
APTT (S) | 1.01 (0.96–1.05) | 0.751 | 0.99 (0.93–1.05) | 0.724 |
FIB | 1.00 (1.00–1.00) | 0.665 | 1.00 (1.00–1.01) | 0.222 |
FDP | 0.98 (0.84–1.14) | 0.783 | 0.94 (0.76–1.15) | 0.528 |
D-dimer | 1.00 (1.00–1.00) | 0.681 | 1.00 (1.00–1.00) | 0.474 |
Model 1: patient- and laboratory-related factors; Model 2: laboratory-related factors.
*p < 0.05, **p < 0.01. Body mass index (BMI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count (WBC), neutrophil ratio (Neu%), hemoglobin (Hb), platelet count (PLT), total protein (TP), albumin level (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), international normalized ratios (INR), fibrin degradation product (FDP), activated partial thromboplastin time (APTT), D-dimer, fibrinogen (Fib), prothrombin time (PT), and plasma thromboplastin antecedent (PT-A).